ClinicalTrials.gov
ClinicalTrials.gov Menu

ACCESS-Europe A Two-Phase Observational Study of the MitraClip® System in Europe (ACCESS-EU)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01288976
Recruitment Status : Completed
First Posted : February 3, 2011
Results First Posted : December 18, 2017
Last Update Posted : April 6, 2018
Sponsor:
Information provided by (Responsible Party):
Evalve

Brief Summary:
The MitraClip System enables the European physicians an alternative therapeutic option for patients with mitral regurgitation (MR). Therapeutic alternatives are open-heart cardiac surgery, and palliative medical therapy with or without device therapy. The study will observe the outcomes of patients treated with the MitraClip System throughout 12-months as compared to the outcomes of patients treated by alternative therapies.

Condition or disease Intervention/treatment
Mitral Valve (MV) Regurgitation Device: MitraClip Drug: Medical Management Procedure: Mitral Valve Surgery

Detailed Description:

PHASE I:

The primary objective of ACCESS-EU Phase I is to gain information in the European Union Countries regarding the use of the MitraClip System with respect to health economics and clinical care.

PHASE II: (HAS BEEN CLOSED BY SPONSOR) The primary objective of ACCESS-EU Phase II is to gather additional clinical data, specifically Echocardiography Core Laboratory measurements of MR severity and left ventricular volumes and diameters, and other echocardiographic measures, on patients undergoing the MitraClip procedure in the European Union Countries,

Clinical data collected from both study phases, is expected to contribute to decision making with regards to MitraClip therapy selection in patients with MR: (a) by establishing the value of the MitraClip therapy in the continuum of care; and (b) by providing practical information that will allow physicians to make therapeutic decisions, assist hospitals to make purchasing decisions, and assist insurers in making coverage decisions.

Study Design:

ACCESS-Europe is a two-phase prospective, observational, multicenter post-approval study of the MitraClip System for the treatment of mitral regurgitation (MR) in the European Union Countries. Patients will be evaluated per standard practice at baseline, discharge, 6-Months and 12-Months.

Phase I of the study consists of patients who receive the MitraClip system for the treatment of MR and two concurrent comparator groups of (a) medically managed heart failure patients with MR and (b) patients who have undergone mitral valve surgery for MR. The two comparator groups will be followed and evaluated primarily from a health economic perspective.

ACCESS EU Study Phase II will consist of only patients who receive the MitraClip System, with the objective to collect additional clinical data, specifically Echocardiography Core Laboratory evaluation of MR severity and other echocardiographic measures.

Enrollment of patients in each study phase is as follows:

ACCESS-EU PHASE I:

  • A minimum of 300 MitraClip Therapy group patients,
  • A minimum of 100 patients in the Mitral Valve Surgery comparator group
  • As many patients as possible in the Medical Therapy comparator group

First Patient Enrollment Projection: Q1, 2009 Last Patient Enrollment Projection: Enrollment in the Mitral Valve Surgery and Medically Therapy groups ceased on December 31, 2010. Enrollment in the MitraClip group will cease when Phase II of the study is initiated at each site.

ACCESS-EU PHASE II:

A minimum of 300 MitraClip therapy subjects will be enrolled in Phase II.

First Patient Enrollment Projection: Q2, 2011 Last Patient Enrollment Projection: Enrollment will cease when the Sponsor has determined that an adequate number of patients have been enrolled.


Study Type : Observational
Actual Enrollment : 721 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: ACCESS-Europe A Two-Phase Observational Study of the MitraClip® System in Europe
Study Start Date : October 2008
Actual Primary Completion Date : June 2012
Actual Study Completion Date : August 2012

Group/Cohort Intervention/treatment
MitraClip Therapy
Patients treated with the MitraClip System.
Device: MitraClip
The MitraClip System includes a MitraClip device, a Steerable Guide Catheter, and a MitraClip Delivery System that enables placement of the MitraClip device on the mitral valve leaflets

Medical Management
Patients with MR managed non-surgically based on standard hospital clinical practice.
Drug: Medical Management
The Non-Surgical Medically Managed Heart Failure (HF) Group consists of patients with mitral regurgitation (MR) in whom the MR is managed non-surgically based on standard hospital clinical practice. Patients with MR who receive a pacemaker, Implantable Cardiac Defibrillator (ICD) and/or Cardiac Resynchronization Therapy (CRT) treatments may be included

Mitral Valve Surgery
Patients with MR managed surgically (repair or replacement) based on standard hospital clinical practice.
Procedure: Mitral Valve Surgery
The Mitral Valve Surgery Group consists of patients with MR in whom the MR is managed surgically (repair or replacement) based on standard hospital clinical practice. Patients with concurrent coronary artery bypass grafting (CABG) or aortic/tricuspid valve or and other cardiac procedure except atrial fibrillation surgery are excluded.




Primary Outcome Measures :
  1. MR Severity [ Time Frame: At baseline ]

    MR Severity: Site-assessed mitral regurgitation severity using echocardiography. MR severity is graded on a scale of 0+ to 4+ where 0+ means absence of mitral regurgitation, 1+ is mild, 1+ to 2+ is mild-to-moderate, 2+ to 3+ is moderate to moderate-to-Severe, 3+ is moderate-to-severe, 3+ to 4+ is moderate-to-severe to severe, 4+ is severe.

    MR severity was not consistently captured for patients in the Medical Management and Mitral Valve Surgery groups. The Medical Therapy & Mitral Valve Surgery comparator groups were followed & studied primarily from a health economic perspective. Availability of clinical outcomes at followup is limited & has not been validated. Clinical outcomes for the comparator groups will not be reported.


  2. MR Severity [ Time Frame: At 12 months ]

    MR Severity: Site-assessed mitral regurgitation severity using echocardiography. MR severity is graded on a scale of 0+ to 4+ where 0+ means absence of mitral regurgitation, 1+ is mild, 1+ to 2+ is mild-to-moderate, 2+ to 3+ is moderate to moderate-to-Severe, 3+ is moderate-to-severe, 3+ to 4+ is moderate-to-severe to severe, 4+ is severe.

    MR severity was not consistently captured for patients in the Medical Management and Mitral Valve Surgery groups. The Medical Therapy & Mitral Valve Surgery comparator groups were followed & studied primarily from a health economic perspective. Availability of clinical outcomes at follow-up is limited & has not been validated. Clinical outcomes for the comparator groups will not be reported.



Secondary Outcome Measures :
  1. Procedure Time [ Time Frame: Day 0 (On the day of procedure) ]
    Procedure Time is defined as the time of start of the transseptal procedure to the time the Steerable Guide Catheter is removed.

  2. Contrast Volume [ Time Frame: Day 0 (On the day of procedure) ]
  3. Fluoroscopy Duration [ Time Frame: Day 0 (On the day of procedure) ]
  4. Number of MitraClip Devices Implanted [ Time Frame: Day 0 (On the day of procedure) ]
    Physicians had the option of deploying more than 1 MitraClip device if a single device did not provide satisfactory MR reduction, and if the mitral valve area was large enough to allow multiple MitraClip devices to be placed without causing mitral stenosis.

  5. ICU and Hospital Stay [ Time Frame: From the day of procedure throughout 12 months of study period ]
    ICU and hospital stay is defined as the mean duration of time that patients spent in the ICU (Intensive Care Unit)/ CCU (Cardiac Care Unit)/ PACU (Post-Anesthesia Care Unit) following the MitraClip procedure. This secondary outcome measure does not apply to the Medical Management or the Mitral Valve Surgery groups.

  6. Discharge Status and Facility [ Time Frame: At discharge, an average of 7.7 days following the MitraClip procedure ]
  7. Discharge MR Severity [ Time Frame: At discharge, an average of 7.7 days following the MitraClip procedure ]
  8. Kaplan-Meier Freedom From All-Cause Mortality [ Time Frame: At 0 day ]
  9. Kaplan-Meier Freedom From All-Cause Mortality [ Time Frame: At 30 days ]
  10. Kaplan-Meier Freedom From All-Cause Mortality [ Time Frame: At 6 months ]
  11. Kaplan-Meier Freedom From All-Cause Mortality [ Time Frame: At 12 months ]
  12. Device Embolization and Single Leaflet Device Attachment [ Time Frame: Through 12 months ]

    Device embolization is defined as bilateral Clip detachment resulting in Clip embolization. Reasons for Clip embolization include leaflet tearing, Clip unlocking, Clip fracture or inadequate Clip placement (i.e., malposition). Not included are any fractures or other failures of the Clip that do not result in Clip detachment from both leaflets.

    Single leaflet device attachment (SLDA) is defined as the loss of insertion of a single leaflet from the MitraClip device with ongoing insertion of the opposing leaflet. SLDAs are reported on ACCESS-EU adverse event log and MitraClip procedure electronic case report forms, and may also be reported by Abbott Vascular personnel per EU Vigilance requirements.


  13. 1-Day Post-Procedure Safety Outcomes [ Time Frame: On day 1 post procedure ]
    This outcome measure does not apply to the Medical Management or the Mitral Valve Surgery groups. Because the Medical Therapy&Mitral Valve Surgery comparator groups were followed&studied primarily from a health economic perspective.Availability of clinical outcomes at follow-up is limited & has not been validated. Clinical outcomes for the comparator groups will not be reported.

  14. Need for Mitral Valve Surgery [ Time Frame: Through 12 months ]
    This end point is assessed on subjects who underwent mitral valve surgery within 12 months post-MitraClip procedure.

  15. NYHA Functional Class [ Time Frame: At baseline ]

    New York Heart Association (NYHA) Functional Classification.

    Class I: Patients with cardiac disease but without resulting limitations of physical activity.

    Class II: Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest.Ordinary physical activity results in fatigue, palpitation, dyspnea or anginal pain.

    Class III: Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest.Less than ordinary physical activity causes fatigue, palpitation dyspnea or anginal pain.

    Class IV: Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort.Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest.If any physical activity is undertaken,discomfort is increased.


  16. NYHA Functional Class [ Time Frame: At 12 month ]

    Defined as assessment of NYHA functional class status at follow-up compared to baseline NYHA functional class status.

    Class I: Patients with cardiac disease but without resulting limitations of physical activity.

    Class II: Patients with cardiac disease resulting in slight limitation of physical activity.Patients are comfortable at rest.Ordinary physical activity results in fatigue, palpitation, dyspnea/anginal pain.

    Class III: Patients with cardiac disease resulting in marked limitation of physical activity.They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation dyspnea/anginal pain Class IV: Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort.Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken,discomfort is increased.


  17. The Change in 6 Minute Walk Test Distance From Baseline to 12 Months [ Time Frame: Baseline and 12 months ]
    It is calculated as a difference between 12 Months and Baseline time points

  18. Change in Minnesota Living With Heart Failure (MLWHF) Quality of Life Score From Baseline to 12 Months [ Time Frame: 12 months ]

    The Minnesota Living with Heart Failure Questionnaire(MLHFQ) is comprised of 21 questions.The response for each question ranges from 0(no affect on the patient's living) to 5(affected the patient's life very much during the past month).The total score for the 21 items can range from 0-105.A lower&higher MLHFQ score indicates less effect of heart failure&the worse impact of heart failure on a patient's QOL,respectively.Although the MLHFQ incorporates relevant aspects of the key dimensions of QOL (physical and emotional),the questionnaire was not designed to measure any particular dimension separately.The total score should be taken as the best measure of how heart failure and treatments impact QOL.

    The total score is the sum of a)the physical dimension,measured using 8 questions (possible subscale score range 0-40) b)the emotional dimension,measured using 5 questions(possible subscale score from 0-25)&c) other factors,measured using 8 questions (possible subscale score from 0-40).


  19. Six Minute Walk Test Distance (6MWT) [ Time Frame: Baseline ]
    The 6-minute walk distance test will be used to measure the patient's exercise capacity.

  20. Six Minute Walk Test Distance (6MWT) [ Time Frame: 12 months ]
    The 6-minute walk distance test will be used to measure the patient's exercise capacity.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with Mitral Regurgitation
Criteria

Inclusion Criteria:

  • Per the current approved labeling for the Conformity European (CE) Marked MitraClip System.

Exclusion Criteria:

  • Per the current approved labeling for the CE Marked MitraClip System.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01288976


Locations
Germany
Universitatsmedizin Gottingen
Gottingen, Germany, 37075
Sponsors and Collaborators
Evalve
Investigators
Study Director: Barathi Sethuraman, PhD Abbott Vascular Structural Heart (Evalve Inc)
Principal Investigator: Wolfgang Schillinger, MD Universitatsmedizin Gottingen
Principal Investigator: Francesco Maisano, MD Fondazion Ctr San Raffaele Del Monte Tabor Istituto

Additional Information:
Publications of Results:
Other Publications:

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Evalve
ClinicalTrials.gov Identifier: NCT01288976     History of Changes
Other Study ID Numbers: EU-0901
First Posted: February 3, 2011    Key Record Dates
Results First Posted: December 18, 2017
Last Update Posted: April 6, 2018
Last Verified: March 2018

Keywords provided by Evalve:
Mitral Valve
Mitral Regurgitation
MitraClip
Mitral Valve Surgery
Mitral Valve Insufficiency or Mitral Regurgitation